Drug:
Reaction: DRUG DOSE OMISSION BY DEVICE
20260101 - 20261231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 26474908 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Product use issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 502 | 26474911 |
US |
||
Drug dose omission by device, Product use issue, Device delivery system issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 503 | 26474913 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 504 | 26474914 |
US |
||
Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 505 | 26474915 |
US |
||
Product use in unapproved indication, Device defective, Device delivery system issue, Wrong technique in device usage process, Drug dose omission by device, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 506 | 26474918 |
US |
||
Drug effective for unapproved indication, Drug dose omission by device, Device delivery system issue, Device issue, Device breakage, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, LISDEXAMFETAMINE DIMESYLATE, SERTRALINE, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 507 | 26474920 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 508 | 26474927 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 509 | 26474930 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 510 | 26474931 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device occlusion, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, ESCITALOPRAM, |
||||
| 511 | 26474942 |
US |
||
Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 512 | 26474951 |
US |
||
Drug dose omission by device, Device delivery system issue, Device malfunction, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 513 | 26474955 |
US |
||
Nasal congestion, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 514 | 26475024 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 515 | 26475025 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 516 | 26475028 |
US |
||
Device delivery system issue, Drug dose omission by device, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 517 | 26475029 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 518 | 26475033 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 519 | 26475035 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Device issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 520 | 26475038 |
US |
||
Drug dose omission by device, Device issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 521 | 26475040 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 522 | 26475043 |
US |
||
Drug dose omission by device, Product use issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 523 | 26475046 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 524 | 26475048 |
US |
||
Sinusitis, Sinus headache, Illness, Product use in unapproved indication, Product odour abnormal, Drug dose omission by device, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 525 | 26475068 |
US |
||
Drug dose omission by device, Device malfunction, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 526 | 26475071 |
US |
||
Drug effective for unapproved indication, Drug dose omission by device, Device malfunction, Device delivery system issue, Device occlusion, Device physical property issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 527 | 26475099 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Wrong technique in device usage process, Product communication issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 528 | 26475102 |
US |
||
Product use in unapproved indication, Wrong technique in device usage process, Device delivery system issue, Device malfunction, Drug dose omission by device, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 529 | 26475106 |
US |
||
Device use issue, Device delivery system issue, Device issue, Drug dose omission by device, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, LOSARTAN, |
||||
| 530 | 26475107 |
US |
||
Product use issue, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 531 | 26475108 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Device occlusion, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 532 | 26475114 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 533 | 26475115 |
US |
||
Drug dose omission by device, Device delivery system issue, Device issue, Device leakage, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 534 | 26475116 |
US |
||
Device delivery system issue, Drug dose omission by device, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 535 | 26475121 |
US |
||
Nasal congestion, Hypersensitivity, Nasal discomfort, Drug dose omission by device, Incorrect dose administered by device, Product use in unapproved indication, Device issue, Device delivery system issue, Product tampering, Product outer packaging issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 536 | 26475124 |
US |
||
Drug dose omission by device, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 537 | 26475125 |
US |
||
Drug dose omission by device, Device delivery system issue, Product use issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 538 | 26475126 |
US |
||
Drug effective for unapproved indication, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, Product tampering, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 539 | 26475133 |
US |
||
Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 540 | 26475141 |
US |
||
Drug dose omission by device, Product cleaning inadequate, Drug ineffective for unapproved indication, Device issue, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 541 | 26475144 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 542 | 26475145 |
US |
||
Intentional dose omission, Drug dose omission by device, Device delivery system issue, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 543 | 26475181 |
US |
||
Drug dose omission by device, Device delivery system issue, Device issue, Product use issue, Drug ineffective for unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, ATORVASTATIN CALCIUM, VALSARTAN, VALSARTAN ORAL, |
||||
| 544 | 26475182 |
US |
||
Product use in unapproved indication, Device delivery system issue, Drug dose omission by device, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 545 | 26475189 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 546 | 26475194 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 547 | 26475202 |
US |
||
Drug dose omission by device, Product use issue, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 548 | 26475207 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 549 | 26475209 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Wrong technique in product usage process, Device delivery system issue, Device defective, Product communication issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 550 | 26475210 |
US |
||
Product use issue, Device occlusion, Device issue, Incorrect dose administered by device, Drug dose omission by device, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 551 | 26475215 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 552 | 26475217 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 553 | 26475218 |
US |
||
Product use in unapproved indication, Product use issue, Drug dose omission by device, Device breakage, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 554 | 26475220 |
US |
||
Drug dose omission by device, Wrong technique in device usage process, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 555 | 26475225 |
US |
||
Nasal ulcer, Product use in unapproved indication, Product use issue, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 556 | 26475327 |
US |
2 | |
Device leakage, Accidental exposure to product, Injection site pain, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 557 | 26475837 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 558 | 26469889 |
US |
66 | 2 |
Headache, Drug dose omission by device, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 559 | 26470475 |
US |
29 | 2 |
Injection site pain, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 560 | 26470615 |
US |
28 | 2 |
Injection site pain, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 561 | 26465711 |
US |
57 | 1 |
Injection site bruising, Injection site pain, Exposure via skin contact, Accidental exposure to product, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 562 | 26466108 |
US |
50 | |
Dyspnoea, Device delivery system issue, Drug dose omission by device, Device deposit issue, Wrong technique in device usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 563 | 26466592 |
US |
55 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LIRAGLUTIDE, |
||||
| 564 | 26468609 |
US |
11 | 1 |
Drug dose omission by device, Device breakage, Device leakage, |
||||
SOMATROPIN, |
||||
| 565 | 26468973 |
US |
76 | 2 |
Drug dose omission by device, Device difficult to use, Blood test abnormal, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 566 | 26469816 |
US |
43 | 2 |
Injection site bruising, Injection site pain, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, DICLOFENAC POTASSIUM, SUMATRIPTAN, SUMATRIPTAN SUCCINATE, HYDROXYZINE, |
||||
| 567 | 26460609 |
US |
64 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, Device deposit issue, Device delivery system issue, Incorrect dose administered by device, Off label use, |
||||
ALBUTEROL SULFATE, |
||||
| 568 | 26460634 |
US |
45 | |
Drug dose omission by device, Device delivery system issue, Device defective, No adverse event, |
||||
ALBUTEROL SULFATE, LISINOPRIL, |
||||
| 569 | 26460642 |
US |
48 | |
Cough, Drug dose omission by device, Wrong technique in product usage process, Device use error, Device occlusion, |
||||
ALBUTEROL SULFATE, |
||||
| 570 | 26460670 |
US |
||
Drug dose omission by device, Wrong technique in product usage process, Wrong technique in device usage process, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 571 | 26461099 |
65 | ||
Gastrointestinal haemorrhage, Infection, Arthralgia, Hypoaesthesia, Herpes zoster, Joint swelling, Psoriasis, Sticky skin, Raynaud^s phenomenon, Mass, Proctocolectomy, Colostomy bag user, Device malfunction, Drug dose omission by device, Device dispensing error, Drug ineffective, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, NAPROXEN, NAPROXEN SODIUM, |
||||
| 572 | 26462191 |
US |
1 | |
Device delivery system issue, Device leakage, Accidental exposure to product, Drug dose omission by device, |
||||
OFATUMUMAB, BUPROPION, BUPROPION HYDROCHLORIDE, ERGOCALCIFEROL, BIOTIN, |
||||
| 573 | 26462232 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 574 | 26462242 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 575 | 26462244 |
US |
||
Drug dose omission by device, Device delivery system issue, Device use issue, Off label use, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 576 | 26462245 |
US |
||
Drug dose omission by device, Device delivery system issue, Device mechanical issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 577 | 26462246 |
US |
||
Drug dose omission by device, Device delivery system issue, Device physical property issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 578 | 26462247 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 579 | 26462249 |
US |
||
Drug dose omission by device, Device delivery system issue, Product packaging quantity issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 580 | 26462775 |
US |
||
Drug dose omission by device, Device delivery system issue, Device mechanical issue, Product quality issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 581 | 26462776 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 582 | 26463205 |
KR |
1 | |
Drug dose omission by device, Device issue, |
||||
SOMATROPIN, |
||||
| 583 | 26463212 |
US |
15 | 1 |
Device issue, Drug dose omission by device, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE, |
||||
| 584 | 26463220 |
CO |
1 | |
Drug dose omission by device, Product expiration date issue, Device information output issue, Device mechanical issue, |
||||
SOMATROPIN, |
||||
| 585 | 26463568 |
US |
16 | |
Injection site haemorrhage, Drug dose omission by device, Device issue, |
||||
FREMANEZUMAB-VFRM, |
||||
| 586 | 26463780 |
AR |
5 | 1 |
Device mechanical issue, Drug dose omission by device, Product prescribing error, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 587 | 26463855 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 588 | 26463857 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 589 | 26463979 |
US |
84 | 1 |
Somnolence, Therapeutic product effect incomplete, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 590 | 26463991 |
US |
1 | |
Hypoacusis, Wrong technique in product usage process, Incorrect disposal of product, Drug dose omission by device, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 591 | 26463994 |
US |
62 | 2 |
Drug dose omission by device, Device difficult to use, Headache, Product communication issue, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 592 | 26464015 |
US |
65 | 1 |
Cough, Device difficult to use, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 593 | 26464670 |
AR |
10 | 2 |
Drug dose omission by device, Device power source issue, |
||||
SOMATROPIN, |
||||
| 594 | 26464900 |
US |
40 | 2 |
Illness, Headache, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, |
||||
| 595 | 26464925 |
US |
||
Drug dose omission by device, Device delivery system issue, Device physical property issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 596 | 26456975 |
US |
63 | 2 |
Arthritis, Drug dose omission by device, |
||||
ETANERCEPT, |
||||
| 597 | 26457669 |
US |
58 | 1 |
Injection site mass, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 598 | 26457771 |
US |
75 | |
Device delivery system issue, Drug dose omission by device, Off label use, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 599 | 26457891 |
US |
68 | 2 |
Headache, Device difficult to use, Drug dose omission by device, Device use error, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 600 | 26458186 |
US |
||
Drug dose omission by device, Product packaging quantity issue, Device malfunction, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28